Actemra/RoActemra is the only approved anti-IL-6 receptor biologic, available in both intravenous (IV) and subcutaneous formulations, for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA). Actemra/RoActemra can be used alone or with methotrexate (MTX) in adults who are intolerant to, or have failed to respond to, other anti-rheumatic medications. In the most recent update to the European League Against Rheumatism (EULAR) RA management guidelines, Actemra/RoActemra is highlighted as the only biologic that has been repeatedly demonstrated to be superior as a monotherapy over MTX or other conventional disease-modifying antirheumatic drugs (DMARDs). Actemra/RoActemra IV formulation is approved in most major countries for polyarticular juvenile idiopathic arthritis (pJIA) and systemic juvenile idiopathic arthritis (sJIA) in children two years of age and older. In Europe, Actemra/RoActemra is also approved for use in patients with severe, active and progressive RA who previously have not been treated with MTX. Actemra/RoActemra is part of a co-development agreement with Chugai Pharmaceutical Co., Ltd and has been approved in Japan since April 2005. Actemra/RoActemra is approved in more than 100 countries worldwide.
Anabolic steroids differ in their characteristics, which means there are steroids that are only suitable for specific uses. For instance, Trenbolone is not recommended for bulking but it is an outstanding fat burner. This makes it perfect for a lean mass cycle or a cutting cycle. Always take the side effects of a particular compound into consideration whenever you plan a stack. Do not combine anabolic steroids that show similar side effects. For example, never combine Anapolon and Dianabol because they are already quite toxic and if you combine them, the toxicity will increase exponentially and cause serious damage to your body.
Register for alerts
If you have registered for alerts, you should use your registered email address as your username